Genetics and therapy of familial hypercholesterolemia

de Sauvage Nolting, P.R.W.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Elevated remnant-like particles in heterozygous familial hypercholesterolemia and response to statin therapy

Circulation 2002; 106:788-792

Pernette R.W. de Sauvage Nolting¹, Marcel B. Twickler², Geesje M. Dallinga-Thie², Rudolf J.A. Buirma³, Barbara A. Hutten¹, John J.P. Kastelein¹; for the ExPRESS study group.

¹Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
²Department of Vascular Medicine, University Medical Center, Utrecht, the Netherlands
³Merck, Sharp & Dohme, Clinical Research, Haarlem, the Netherlands
⁴Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, the Netherlands.
Chapter 6

ABSTRACT

BACKGROUND
Remnant lipoproteins (RLP-C) are considered important in atherogenesis. Hence, this study was designed to assess RLP-C levels and the effect of statin therapy in patients with familial hypercholesterolemia (FH). Elevated RLP-C levels have been associated with the presence and progression of atherosclerotic disease and their presence in FH patients has been proposed but never established in a large cohort, or their response to statin therapy.

METHODS AND RESULTS
FH patients were recruited from 37 Lipid Clinics. After a washout period of 6 weeks, all patients were started on monotherapy with 80 mg simvastatin for two years. RLP-C levels were assessed by an immune-separation assay. In 327 FH patients RLP-C measurements could be performed before and after treatment. Mean total (10.55 ± 2.17 mmol/L), mean LDL cholesterol (8.40 ± 2.13 mmol/L) and median RLP-C (0.47 mmol/L) levels were all severely elevated at baseline. After treatment, RLP-C levels were reduced by 49% (0.24 mmol/L; p<0.0001). Even patients with normal TG levels had elevated RLP-C levels at baseline and those with high RLP-C levels were generally characterized by a very atherogenic lipoprotein profile.

CONCLUSIONS
Baseline RLP-C levels are severely elevated in FH patients, are reduced by simvastatin, but do not return to normal. These elevated RLP-C levels could be the consequence of impaired function of the LDL-receptor in FH. RLP-C levels in FH contribute to an atherogenic lipoprotein profile and could identify patients who require additional treatment.
INTRODUCTION

LDL-cholesterol and atherogenesis
Familial Hypercholesterolemia (FH) is an autosomal dominant disorder of lipoprotein metabolism. Mutations in the LDL-receptor gene are the cause of this disease and lead to a reduction in the clearance of LDL-cholesterol (LDL-C), which consequently causes a rise in LDL-C levels and predisposes to the development of atherosclerosis. Therefore, FH patients are at great risk of developing premature coronary artery disease (CAD). However, there is a wide variation of coronary risk among FH patients.

Remnant lipoproteins and atherogenesis
Increasing experimental and clinical evidence suggests that triglyceride-rich lipoproteins (TRL) and in particular remnant-like particles (RLP) contribute to atherogenesis and consequently to cardiovascular disease progression. High levels of remnant lipoproteins of both hepatic (very-low-density lipoproteins (VLDL)) and intestinal (chylomicron) origin are associated with the progression of coronary atherosclerosis. In a study of Phillips et al, it was found that neither LDL-C nor triglyceride (TG) levels correlate well with lesion progression or clinical events. TRL remnant levels, however, did correlate with both lesion progression and cardiac events. Recently, Nakajima et al developed a simple technique to analyze remnant-like particle cholesterol (RLP-C) using an immune-affinity gel containing anti-apolipoprotein (apo) A-I and anti-apoB100 monoclonal antibodies. This unique anti-apoB100 monoclonal antibody was shown to recognize apoB100 in LDL and most VLDL but not in apoE-enriched VLDL, whereas anti-apoA-I recognizes and binds all HDL particles. This technique isolates apoE-rich VLDL particles containing apoB100 together with chylomicron remnants containing apoB48, neither of which binds to the immunoaffinity gel. Increased levels of these remnant particles have already been associated with the presence and progression of cardiovascular disease (CVD) and with endothelial dysfunction. However, it should be stressed that these previous results are examined in non-FH patients. Evidently, these patients have a different lipid profile compared to the extremely elevated LDL-C levels seen in FH patients. Therefore, this association between elevated levels of RLP-C and CVD cannot be extrapolated to FH patients as such.

Levels of remnant particles could be relevant for the understanding of the heterogeneity in coronary risk among FH patients. RLP-C levels have so far not been assessed in a large FH population. Up to now only two small studies (in 15 and
7 FH patients, respectively) reported RLP-C levels of FH patients and did indeed show increased RLP-C levels.\textsuperscript{19,30} In the current study we aimed to assess accumulation of RLP-C and also to evaluate whether RLP-C levels will be lowered by statin therapy in a large and well-defined cohort of FH patients.

**METHODS**

**Subjects**
The present study is a substudy of the ExPRESS FH (Examination of Probands and Relatives in Statin Studies with Familial Hypercholesterolemia) study, in which efficacy, safety and pharmacogenomics of simvastatin 80 mg was assessed in 526 heterozygous FH patients. For this open label multicenter study FH patients were recruited from 37 Lipid Clinics in the Netherlands. Patients were included if they met the following criteria: all patients had to have either a molecular diagnosis for FH or were diagnosed with definite FH and had to have 6 or more points, according to an algorithm (to allow standardization of the diagnosis of FH based on clinical findings, personal and familial clinical history and biochemical parameters)\textsuperscript{21}; at least 18 years of age; and patients with a history of myocardial infarction (MI), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angiography (PTCA) could be included if the physician thought it was medically allowed for the patient to have a washout period. Patients were excluded if they: were pregnant or nursing women, or pre-menopausal women not using adequate contraceptives; had acute liver disease, hepatic dysfunction, or persistent elevations of serum transaminases; had hypersensitivity or intolerance to simvastatin or any of its components; had hyperlipidemia Type I, III, IV or V or homozygous FH; had a recent history of alcohol or drug abuse; had secondary hypercholesterolemia due to any cause; had inadequately controlled diabetes, unstable angina or intermediate coronary syndrome or clinically significant ventricular arrhythmia at study entry or MI within the past 3 months; were on concurrent use of erythromycin and similar drugs affecting the cytochrome P450 enzyme; had a history of cancer.

**Controls**
Controls for the 327 FH patients, in whom RLP-C levels were measured, were recruited post-hoc from their families and matched for age and sex. In these 77 individuals we obtained demographic characteristics, lipids and lipoproteins.
Study design
After a washout period of six weeks, patients were started on monotherapy with simvastatin 80 mg. No other lipid lowering medication was allowed. Medical history, physical examination and additional risk factors for cardiovascular disease as well as laboratory analysis of lipid and lipoprotein levels and routine safety parameters were obtained in all patients. The biochemical analyses of lipid levels and safety parameters were performed in the hospitals themselves and were standardized by a virtual central laboratory. The apolipoprotein determinations were performed in the Academic Medical Center in Amsterdam and the RLP determinations in the University Medical Center in Utrecht. The Ethics Committees of all the 37 centers approved the protocol and written informed consent was obtained from all participants.

Biochemical analysis
Blood samples were taken in the morning after an overnight fast. Total cholesterol (TC), HDL-cholesterol (HDL-C) and triglycerides (TG) were routinely determined in the different laboratories and standardized by a virtual central laboratory. LDL-C was calculated using the Friedewald formula. Apolipoprotein A-I (apoA-I) and apolipoprotein B (apoB) were determined by an immunological rate-nephelometric procedure using a polyclonal goat anti-human antibody (Array protein system, Beckman Coulter, Netherlands).

The RLP fraction was prepared by use of an immune-separation technique described by Campos, Nakajima and colleagues. Briefly, 5 μL of serum was added to 300 μL of mixed immunoaffinity gel suspension containing monoclonal anti-human apoA-I (H-12) and anti-human apoB100 (JI-H) antibodies (Japan, Immunoresearch Laboratories, Takasaki, Japan). The reaction mixture was gently shaken for 120 minutes at room temperature. After the supernatant was left standing for 15 minutes, 200 μL was withdrawn for the assay of RLP-C. Cholesterol in the RLP fraction (coefficient of variation <3%) was measured by an enzymatic assay on a Cobas Mira S auto analyzer (ABX Diagnostics, Montpellier, France). Apo E genotyping was performed as described by Reymer et al.

Statistical analysis
Data were expressed as mean ± standard deviation. Skewed data distributions were presented as median and the interquartile range. Mean and median cholesterol levels in FH patients compared to controls were tested by the independent sample t-test and the Mann-Whitney test, respectively. Mean values in lipids, lipoproteins before
and after treatment were compared using the paired sample t-test. TG and RLP-C were compared by the non-parametric Wilcoxon test, because they had a skewed distribution. Mean values in baseline characteristics and lipids for the different groups were compared using the one-way ANOVA test. Parameters with a skewed distribution (TG, RLP-C and RLP reduction) were compared using the Kruskal-Wallis test. Chi-square tests were applied for comparing distributions of dichotomous data (gender, diabetes and apoE2). All statistical analyses were performed using the SPSS package (version 10.1, Chicago; Illinois). A p-value of less than 0.05 was considered to be statistically significant.

**RESULTS**

From the 526 patients, participating in the ExPRESS FH study blood samples were stored in 327 patients. Consequently, these patients were available for RLP-C analyses and comprised our study group. This group did not differ from the source population with regard to baseline characteristics and lipid parameters. Ages ranged from 18 to 80 years. Mean age was 47.4 years (standard deviation (SD) ± 13.2). Slightly more males (54%) than females (46%) were included. Mean body mass index (BMI) was 25.8 kg/m² (SD ± 3.6). Lifestyle and physical characteristics such as dietary adherence, BMI, alcohol intake and physical exercise did not change over the course of the trial.

**Table 1.** Lipid, lipoprotein and RLP-C levels in controls and in FH patients at baseline and after one year of therapy.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Baseline (n = 327)</th>
<th>Simvastatin 80 mg (n = 327)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC (mmol/L)</td>
<td>10.55 ± 2.17</td>
<td>6.36 ± 1.37</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>LDL-C (mmol/L)</td>
<td>8.40 ± 2.13</td>
<td>4.32 ± 1.30</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>HDL-C (mmol/L)</td>
<td>1.25 ± 0.35</td>
<td>1.39 ± 0.39</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>TG (mmol/L)</td>
<td>1.80 (1.20-2.40)</td>
<td>1.20 (0.90-1.73)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>ApoA-I (g/L)</td>
<td>1.24 ± 0.22</td>
<td>1.36 ± 0.24</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>ApoB (g/L)</td>
<td>1.97 ± 0.45</td>
<td>1.19 ± 0.31</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>RLP-C (mmol/L)</td>
<td>0.47 (0.34-0.80)</td>
<td>0.24 (0.20-0.31)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

RLP-C, remnant-like particle cholesterol; FH, familial hypercholesterolemia; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; Apo, apolipoprotein. All values are given as mean with SD except that TG and RLP-C are given as median with interquartile range.
Mean lipid, lipoprotein and RLP-C levels at baseline and one year after therapy with simvastatin 80 mg are shown in Table 1. As expected, mean TC (10.55 ± 2.17 mmol/L) levels were severely elevated in FH patients compared to their family controls (4.58 ± 0.77 mmol/L; p<0.0001) and this could largely be attributed to elevated LDL-C levels (8.40 ± 2.13 mmol/L). Mean HDL-C levels were lower in FH patients compared to the controls (1.25 ± 0.35 mmol/L vs. 1.39 ± 0.38 mmol/L; p=0.04), whereas median TG levels were elevated compared to the controls (1.80 mmol/L vs. 0.97 mmol/L; p<0.0001). Median RLP-C levels (0.47 mmol/L) were severely elevated in FH patients. Median RLP-C levels in controls were 0.20 mmol/L, which indicates that FH patients have a twofold elevation of RLP-C levels (p<0.0001). After simvastatin treatment, plasma cholesterol, LDL-C, TG and apoB decreased, and HDL-C and apoA-I increased, all significantly. RLP-C levels decreased significantly from a median of 0.47 mmol/L to 0.24 mmol/L (p<0.0001), which is consistent with a 49% median reduction. At baseline, only 5 FH patients (1.5%) had normal RLP-C levels (≤0.20 mmol/L); in contrast after simvastatin therapy 84 patients (25.7%) were below this RLP-C level.

Table 2. Lipids, RLP, ApoE2 and clinical features in FH patients with baseline RLP-C levels divided in 3 equal groups.

<table>
<thead>
<tr>
<th>Variable</th>
<th>RLP-C &lt;0.39 (n = 109)</th>
<th>0.39≤ RLP-C &lt;0.65 (n = 109)</th>
<th>RLP-C ≥ 0.65 (n = 109)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>44.0 ± 14.2</td>
<td>46.6 ± 13.2</td>
<td>51.5 ± 11.0</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Male gender (n)</td>
<td>41 (45.0%)</td>
<td>47 (51.4%)</td>
<td>60 (65.1%)</td>
<td>0.009</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.6 ± 3.7</td>
<td>25.6 ± 3.2</td>
<td>27.3 ± 3.5</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Diabetes (n)</td>
<td>0 (0%)</td>
<td>1 (0.9%)</td>
<td>5 (4.6%)</td>
<td>0.029</td>
</tr>
<tr>
<td>TC (mmol/L)</td>
<td>9.50 ± 1.70</td>
<td>10.68 ± 2.08</td>
<td>11.47 ± 2.23</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>LDL-C (mmol/L)</td>
<td>7.58 ± 1.63</td>
<td>8.64 ± 2.13</td>
<td>8.99 ± 2.32</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>HDL-C (mmol/L)</td>
<td>1.37 ± 0.36</td>
<td>1.29 ± 0.35</td>
<td>1.09 ± 0.27</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>TG (mmol/L)</td>
<td>1.10 (0.90-1.50)</td>
<td>1.80 (1.30-2.05)</td>
<td>2.80 (2.10-3.60)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>ApoA-I (g/L)</td>
<td>1.28 ± 0.21</td>
<td>1.25 ± 0.24</td>
<td>1.18 ± 0.19</td>
<td>0.004</td>
</tr>
<tr>
<td>ApoB (g/L)</td>
<td>1.74 ± 0.35</td>
<td>2.00 ± 0.39</td>
<td>2.17 ± 0.49</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>RLP-C (mmol/L)</td>
<td>0.32 (0.26-0.34)</td>
<td>0.47 (0.43-0.53)</td>
<td>1.06 (0.79-1.62)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>RLP reduction (%)</td>
<td>29.0 (14.9-41.0)</td>
<td>50.5 (39.8-57.7)</td>
<td>67.5 (57.2-76.8)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>ApoE2 allele (n)</td>
<td>5 (4.6%)</td>
<td>4 (3.7%)</td>
<td>17 (15.6%)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

FH, familial hypercholesterolemia; RLP-C, remnant-like particle cholesterol; BMI, body mass index; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; Apo, apolipoprotein. All values are given as mean with SD or (%), except that TG, RLP-C and RLP-C reduction are given as median with interquartile range.
In Table 2, baseline RLP-C levels are divided into 3 equal groups by the 33rd and 66th percentiles. FH patients in the highest third were older, more often male, had a higher BMI and had more often diabetes. To address whether FH patients with type 2 diabetes were outliers in terms of remnant accumulation and caused significant shifts of the medians in the different groups, we calculated median RLP-C levels with these individuals included or excluded. However, results indicated no significant changes in the medians of these 3 groups (data not shown). In addition, the statistically significant increase in total cholesterol, LDL-C and TG levels and the decrease in HDL-C, illustrates the association between plasma RLP-C and the presence of a severe atherogenic lipoprotein profile. RLP-C levels were also correlated to HDL-C levels, the Spearman's rank correlation coefficient was $r = -0.37$ at $p<0.0001$. In the lowest third of baseline RLP-C levels, median TG levels were normal (1.10 mmol/L) whereas in that third median RLP-C levels were still above normal (0.32 mmol/L). Moreover, significantly more patients in the highest RLP-C third had an apoE2 allele compared to the two lower thirds ($p=0.001$). Lastly, RLP-C levels were more reduced in the highest third compared to the lower thirds. Since pre- and post treatment measurements on the variable of interest are, in general, not perfectly correlated, the evaluation of treatment effects must be adjusted for regression to the mean. Chen et al. proposed 4 models, which included either or both additive and multiplicative effects. We have applied this model to evaluate RLP-C changes. The model, which included both additive and multiplicative effects fit better than that with only additive effects (regression to the mean) for RLP-C change ($p<0.0001$). Therefore, changes in RLP-C could not be attributed to regression to the mean only, but indeed exhibit a relationship with baseline levels. FH patients in the highest versus the lowest third of RLP-C suffered from CVD in 53 (48.6%) versus 30 (27.5%) of cases ($\chi^2=10.5$, $p=0.005$). However, upon multiple logistic regression analysis with age, gender, BMI and major lipids in the model this relation was no longer statistically significant ($p=0.32$).

In Table 3 the data were stratified according to baseline TG levels in quartiles. Patients in the lowest quartile had completely normal median baseline TG levels (0.90 mmol/L), however the corresponding RLP-C levels were already strongly elevated (0.32 mmol/L), whereas plasma LDL-C levels were similar in all groups ($p=0.09$).
Elevate RPL-C and therapy response

Table 3. Lipids and RLP-C levels in FH patients with baseline TG levels divided in quartiles (all in mmol/L).

<table>
<thead>
<tr>
<th></th>
<th>TG ≤ 1.10</th>
<th>1.10&lt;TG ≤ 1.80</th>
<th>1.80&lt;TG ≤ 2.40</th>
<th>TG &gt;2.40</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n=80)</td>
<td>(n=91)</td>
<td>(n=76)</td>
<td>(n=80)</td>
<td></td>
</tr>
<tr>
<td>LDL-C</td>
<td>8.03 ± 1.90</td>
<td>8.81 ± 2.17</td>
<td>8.48 ± 2.30</td>
<td>8.23 ± 2.07</td>
<td>0.09</td>
</tr>
<tr>
<td>TG</td>
<td>0.90 (0.80-1.00)</td>
<td>1.50 (1.30-1.70)</td>
<td>2.10 (1.90-2.20)</td>
<td>3.25 (2.73-4.10)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>RLP-C</td>
<td>0.32 (0.25-0.41)</td>
<td>0.42 (0.33-0.49)</td>
<td>0.52 (0.42-0.75)</td>
<td>1.16 (0.79-1.80)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

RLP-C, remnant-like particle cholesterol; FH, familial hypercholesterolemia; TG, triglycerides; LDL-C, low-density lipoprotein cholesterol. LDL-C is given as mean with SD; TG and RLP-C are given as median with interquartile range.

DISCUSSION

RLP-C increase at baseline

In this study we observed that median RLP-C levels in FH patients are severely elevated compared to their siblings (0.47 mmol/L vs. 0.20 mmol/L; p<0.0001). Elevated RLP-C levels were reported before in FH patients, albeit in very small cohorts. Twickler et al measured RLP-C levels in 7 FH patients and found significantly elevated mean RLP-C levels compared with 7 controls (42.10 mg/dl (1.09 mmol/L) vs. 7.49 mg/dl (0.19 mmol/L); p<0.01). Dane-Stewart et al. also found elevated median RLP-C levels in 15 FH patients compared with 15 controls (16.2 mg/dl (0.42 mmol/L) vs. 8.5 mg/dl (0.22 mmol/L); p=0.003). In our cohort, mean age and BMI increase from the lowest to the highest RLP-C thirds. Why RLP levels rise with age is unknown, but older people have higher BMI's often combined with higher TG levels. This association points to increased synthesis of VLDL, which could consequently lead to higher RLP levels. We also found a higher prevalence of apoE2 allele carriers in the highest RLP-C third. ApoE is the major ligand for hepatic lipoprotein receptors and mediates chylomicon and VLDL remnant uptake. ApoE2 is one of the three E isoforms and exhibits a very low affinity to the LDL-receptor. It is therefore not unexpected to find more apoE2 alleles in the highest third of RLP-C levels. The apoE allele distribution was in Hardy Weinberg equilibrium (χ² =3.59, p>0.1) in our FH sample but the frequency of the e2 allele was lower compared to the general Dutch population as previously reported (0.047 and 0.082, respectively). It is therefore unlikely that an overrepresentation of the e2 allele of the apoE gene will have contributed to our findings.
These elevated RLP-C levels might play an important role, in addition to elevated LDL-C levels, in the acceleration of atherosclerosis in FH. This idea is supported by the findings of Karpe et al. who did not find an association between LDL-C and new lesions in vein grafts in 395 patients with coronary artery disease (CAD), but did find a strong trend for higher RLP-C concentrations.\textsuperscript{17}

**RLP-C reduction after statin intervention**

RLP-C levels are significantly decreased by simvastatin. Median RLP-C levels almost returned to normal, but remained slightly elevated. This observation was previously reported in 7 FH patients.\textsuperscript{20} Recently, two studies in patients with combined dyslipidemia showed similar results.\textsuperscript{30,31} Stein et al found that median elevated RLP-C levels of 0.34 mmol/L were reduced by simvastatin 20 mg (6.0%) and by atorvastatin 10 mg (25.9%), but not by pravastatin 40 mg in 22 patients in a crossover study.\textsuperscript{30} In addition, Sasaki et al found that atorvastatin 10 to 20 mg reduced RLP-C levels from 0.31 mmol/L to 0.16 mmol/L.\textsuperscript{31} These studies also illustrate a treatment effect of statins on the RLP-C fraction.

**Accumulation as the proposed mechanism**

The central abnormality in heterozygous FH is an impaired function of the LDL receptor. As a consequence, plasma levels of LDL-C are severely elevated, and levels of RLP-C as well. Moreover, these elevated RLP-C levels are significantly reduced by simvastatin treatment. Statins likely improve RLP clearance by upregulating LDL-receptors and by decreasing hepatic VLDL synthesis.\textsuperscript{32,33} Both mechanisms lead to less competition for the clearance mechanisms shared by chylomicrons and VLDL.\textsuperscript{34} The reductions in apoB and LDL-C were very consistent with those of RLP-C, as is anticipated since by upregulating the LDL (apoB, E) receptor all apoB (LDL) as well as apoE (RLP-C) containing lipoproteins will be reduced in essentially similar proportions.

The raised TG levels in the higher RLP-C thirds support the accumulation of TG-rich lipoproteins. The conclusion could therefore be drawn that TG levels measured in FH patients primarily reflect atherogenic remnant lipoproteins. However, even patients with normal TG levels had elevated RLP-C levels. This observation was also made previously.\textsuperscript{20} All these data indicate the presence of remnant particle accumulation in FH patients, irrespective of concomitant TG elevation. Likewise, stratification of the data according to baseline TG into quartiles resulted in an association between TG and RLP-C levels, but LDL-C levels were equally elevated in
Elevated RPL-C and therapy response

all quartiles. This suggests that despite the fact that plasma LDL-C levels are strongly elevated in FH patients, RLP-C levels could further contribute to the atherogenic lipoprotein profile over and above LDL-C measurements. We, therefore, hypothesize, that remnant accumulation in FH might be explained by a combination of factors such as the LDL-receptor mutation, VLDL production associated with advancing age, central obesity and glucose intolerance, carriership of an ε2 allele of the apo E gene and possibly by defective LDL-receptor related protein function. These findings may raise the need to prescribe combination therapy with simvastatin 80 mg and either nicotinic acid or fenofibrate or with more powerful statins to lower the risk associated with the residual remnant increase.

In conclusion, baseline RLP-C levels are severely elevated in FH patients. Treatment with high-dose simvastatin resulted in a strong reduction of RLP-C, but in the majority of patients, RLP-C levels remained elevated. RLP-C levels in FH contribute to an atherogenic lipoprotein profile and could identify patients who require additional treatment.

REFERENCES


